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Incomplete eradication of the malignant clones in high-riskde novo acute myeloid leukemia (AML), myelodysplasticsyndrome (MDS) and secondary AML (sAML) is the main
cause of treatment failure, demonstrated by a relatively low
complete remission (CR) rate and a high early relapse rate of
more than 50%, unless treated by allogeneic hematopoietic
stem cell transplantation (AHCT). High-risk features include
age 60 years or older, co-morbidities, preceding MDS, and
adverse risk (cyto)genetic risk factors.1 Therefore, new stud-
ies focus on new and better remission-induction and consoli-
dation regimens containing innovative agents. Gemtuzumab
ozogamicin (GO) consists of a humanized anti-CD33 mono-
clonal antibody linked to calicheamicin, a potent antitumor
antibiotic.2 GO binds to CD33, an antigen expressed on the
surface of more than 90% of AML blast cells. Binding of GO
is followed by internalization and toxin release intracellularly
leading to DNA damage and cell death.3 In studies of older
patients with AML in first relapse, tolerable toxicity and a
response rate of 30% was reported following two infusions
of GO 9 mg/m2, although full platelet recovery did not occur
in roughly half of responders.4 These results led to regulatory
approval of the drug in the United States for use in older
patients in first relapse for whom standard therapy was
unsuitable, setting the stage for its evaluation in patients with
newly diagnosed high-risk AML/MDS. However, GO was
voluntarily withdrawn from the market in 2010 on the basis
of preliminary results from a phase III Southwest Oncology
Group (SWOG) randomized study in 673 young adults with
untreated AML.5 This study compared the addition of single
infusion of 6 mg/m2 on day 4 of the first remission-induction
course (daunorubicin (45 mg/m2 on days 1, 2, 3) and cytara-
bine (100 mg/m2 per day by continuous infusion on days 1-7)
versus standard induction therapy with daunorubicin (60
mg/m2 on days 1-3) and cytarabine alone by continuous infu-
sion on days 1 through 7 (DA). The CR rate was 69% for
DA+GO and 70% for DA. The overall efficacy, as measured
by the relapse-free survival and the overall survival (OS), was
similar in both groups. However, the induction mortality was
increased in the DA+GO group, at 5% versus 1% in the DA
group.
Since then, several randomized studies combining GO
with intensive chemotherapy in patients with newly diag-
nosed AML have been reported in the literature providing
new evidence on the clinical efficacy and safety of the
immunoconjugate. A recent meta-analysis of 5 prospective
studies, including the final data from the SWOG5 (total
n=3325 patients)6 showed that addition of GO did not
increase the proportion of patients entering CR with an odds
ratio (OR) of 0.91 and a 95% confidence interval (CI) of 0.77-
1.07 (P=0.3). However, the addition of GO significantly
improved survival (OR 0.90; 95%CI: 0.82-0.98, P=0.03),
although the 5-year OS difference was only around 3%:
35.5% (GO arm) versus 32.2% (control group). Unfortunately,
patients with adverse cytogenetic characteristics did not ben-
efit from the addition of GO in contrast to patients with
favorable or intermediate cytogenetic features who did bene-
fit.6 The great majority of patients in this meta-analysis were
patients with de novo AML. Only two studies7,8 included
patients with sAML and only one study included HR-MDS
patients.8 Increased toxicity and an absence of clinical benefit
were observed in the EORTC/GIMEMA study, in which sin-
gle-agent GO administration preceded induction chemother-
apy.9
As reported in this issue of the Journal, Burnett and co-
workers evaluated two doses of GO (6 vs. 3 mg/m2) in a large
prospective, randomized trial: the National Cancer Research
Institute (NCRI) AML17 trial.10 GO was usually administered
as a single infusion on day 1 of the remission-induction
course. They assessed the toxicity profile and antitumor
activity of GO in combination with a chemotherapy remis-
sion-induction regimen in 673 adults (85%) with untreated de
novo AML, 42 patients (5%) with high-risk MDS (HR-MDS)
(defined as MDS with BM blasts higher than 10%), and 73
patients (9%) with sAML. There was no difference in overall
response rate [defined as complete remission (CR) or CR with
incomplete hematopoietic recovery (CRi)] between the two
evaluated dose levels. All patients received various schedules
of chemotherapy without GO after the first remission-induc-
tion course, depending on the risk status after the first remis-
sion-induction course and the presence of FLT-3 abnormali-
ties. The overall survival and relapse risk did not differ
despite a higher non-relapse (early) mortality and veno-occlu-
sive disease (VOD) in the higher GO group (6 mg/m2). In
addition, grade 3-4 serious adverse events (SAEs) were signif-
icantly higher in the higher dose GO group. Subgroup analy-
sis did not show any difference in outcome in any subgroup.
This large randomized study did not show any significant
benefit of using GO at the 6 mg/m2 dose, although there was
a possible trend for benefit in the adverse risk patients, who
have not been shown to benefit from addition of GO in other
trials. The 6 mg/m2 dose did have a detrimental effect with
respect to liver toxicity and platelet count recovery; therefore,
the outcome of this study suggests that, where a single dose
schedule is used, the 3 mg/m2 dose might be preferred.
The question remains as to whether fractionated dosing
using the lower dose of 3 g/m2 results in better outcome or
whether addition of GO to the consolidation course(s) may
increase the benefit without additional toxicity, and the
authors present a comprehensive discussion of this. It is pos-
sible that a more fractionated schedule with a higher total
dose of GO might be a more effective strategy, which may
take advantage of the CD33-re-expression that occurs after
initial exposure to GO.11 The French ALFA group utilized a
GO schedule of 3 mg/m2/day on days 1, 4 and 7 during
induction chemotherapy, followed by a single dose in each
of two post induction courses, in patients aged 50-70 years
with untreated de novo AML. Complete response was 81%
and event-free survival was 40.8% compared to 17.1% in
the control group (P=0.003).12 It is plausible that at least
some of the benefit was achieved by dosing in consolida-
tion, but also the fractionation of the total GO dose dur-
ing induction may have contributed to the most promi-
nent effect in this French ALFA group study. This benefit
was also apparent in patients with unfavorable cytoge-
netic characteristics, but the impact of complex karyotype
has not been analyzed separately.12 In addition, early mor-
tality seems to be reduced when a dose of 3 g/m2 is used
either as a single dose or in a fractionated schedule.6
There was some hematologic toxicity, particularly to
platelets. So, while a 3 mg/m2 dose appears adequate, it is
still not certain what is the optimal schedule. 
However, the MRC AML15 trial did not show any
additional benefit of adding GO to consolidation irrespec-
tive of whether it had been given with the first induction
course;7 therefore the urgent issue to be resolved is
whether a single dose or a fractionated schedule is to
become the standard approach. In an attempt to do this,
the NCRI have initiated a direct comparison of a 3 mg/m2
dose on day 1 versus days 1 and 4 in their ongoing trials.
In conclusion, data from this study and from studies
published after the withdrawal of GO from the market
support the need for a re-appraisal of the regulatory
approval of GO by the responsible authorities, at least for
certain subtypes of AML. 
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The outcome for T-cell acute lymphoblastic leukemia(T-ALL) has strongly improved over the last decadesusing high-intensity treatment protocols approach-
ing cure rates of 80% for pediatric patients and 60% for
adult patients. Fifteen percent of pediatric ALL patients
present with T-ALL, and they represent nearly half of the
ALL patients who require the most intensive treatment.
Intensive chemotherapy increases the risk for treatment
related morbidity and mortality. For relapsed patients, the
outcome is poor, as T-ALL cells in those patients are highly
resistant to further treatment. Therefore, patient-tailored
treatment and the introduction of high precision medi-
cines remain important. Molecular cytogenetic characteri-
zation of T-ALL has greatly increased our understanding
of the pathogenic events that drive this disease. In contrast
to precursor B-ALL, this improved insight into T-ALL has
not yet yielded prognostic factors that allow for the iden-
tification of patients at high-risk of relapse and who may
be eligible to receive alternative treatment, including allo-
geneic stem cell transplantation.
One cytogenetic entity in pediatric and adult T-ALL
patients that has been suspected to cause poor outcome
include patients bearing a CALM-AF10 (PICALM-
MLLT10) fusion as a consequence of a t(10;11)(p13.14;q14-
21) chromosomal translocation.1 A first systematic study
comprising unselected pediatric and adult T-ALL patients
treated on FRALLE-93, FRALLE 2000 or LALA-94 proto-
cols identified the CALM-AF10 fusion in approximately
9% of patients. This fusion is associated with early and
late T-cell developmental arrest in the γδ lineage. In this
study, late CALM-AF10+ T-ALL patients responded well to
therapy, but 2 out of 12 CALM-AF10+ patients with an
immature phenotype did not respond to therapy, and
another 8  patients with an immature phenotype
